Advanced BioDesign

Company

Advanced BioDesign is a clinical stage biotechnology company founded in Advanced Biodesign is driven by the ambition to treat all patients facing chemotherapy-resistant cancers with elevated levels of ALDH1.   

Since its inception in 2010, this French biotechnology company has  

• confirmed the pivotal role of ALDH1 enzymes in the metabolism of cancer cells and immunomodulation. 

• developed a pipeline of several ALDH1 inhibitors with the potential to be a game changer in the patient care. 

• entered clinical trial in early 2023 with its lead ABD 3001 targeting acute myeloid leukemia (AML). Initial results suggest a good safety profile.  The second generation of ALDH inhibitor, ABD-0171, is developed in solid tumors and has a potentiated effect in combination with anti-PD1. Interesting preclinical data to share  

• developed a predictive and prognostic test called ALDESCREEN® to identify and stratify patients.  Our innovative strategy aims to overcome tumour chemoresistance and to restore or activate endogenous cell death mechanisms in cancer cells. 

Our lead drug candidate, ABD-3001, is a small-molecules inhibitor of the ALDH family of enzymes that is at the initial stage of clinical development for a wide range of cancers, including acute myeloid leukemia, non-small cell lung cancer, melanoma and others.